Group A Streptococcus bacteria — the cause of strep throat and flesh-eating infections — have been well studied for nearly a century. But researchers at University of California San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences recently made a surprising discovery: strep’s M protein alone wipes out macrophages, but not other types of immune cells. The macrophages’ self-sacrifice serves as an early warning of infection to the rest of the immune system.
For surfers, finding the “sweet spot,” the most powerful part of the wave, is part of the thrill and the challenge. Scripps Institution of Oceanography at the University of California postdoctoral researcher Nick Pizzo has found the exact location on the wave where a surfer gains the greatest speed to get the best ride.
On Sunday, May 21, the Student Run Free Clinic Project at UC San Diego was recognized by the American Psychiatric Association (APA) for excellence in caring for the community. For two decades, the Student-Run Free Clinic Project has helped people of all ages and circumstances access high-quality health care, regardless of their ability to pay. The project assists community members with a range of critical health services, including psychiatric care.
Antiva Biosciences, a spinout of UC San Diego, closed a $22M Series C financing in March. Antiva is a clinical stage biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by Human Papilloma Virus (HPV) infection. Osage University Partners, a venture capital firm partnered with UC San Diego that invests exclusively in startups that are commercializing university research, invested in this round.
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System (FAERS) database for depression symptoms in patients taking ketamine for pain. They found that depression was reported half as often among the more than 41,000 patients who took ketamine, as compared to patients who took any other drug or drug combination for pain.
The next installment of the UC San Diego series, Evening with an Entrepreneur, will feature scientist, inventor, serial entrepreneur, innovator, and long-time UC San Diego supporter, Dr. Tina Nova. Nova will sit down with Biocom’s Joe Panetta for an interview to discuss her unique entrepreneurial background and success in molecular diagnostics.
